Serum levels of IL-17A in patients with relapsing–remitting multiple sclerosis treated with interferon-β

• Published in: Multiple sclerosis Vol. 19; no. 7; pp. 885 - 890
• Main Authors: Bălaşa, Rodica, Bajko, Zoltan, Huţanu, Adina
• Format: Journal Article
• Language: English
• Published: London, England SAGE Publications 01.06.2013; Sage Publications
• Subjects: Adult; Biological and medical sciences; Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases; Drug Resistance; Female; Humans; Immunologic Factors - therapeutic use; Interferon-beta - therapeutic use; Interleukin-17 - blood; Male; Medical sciences; Multiple sclerosis and variants. Guillain barré syndrome and other inflammatory polyneuropathies. Leukoencephalitis; Multiple Sclerosis, Relapsing-Remitting - blood; Multiple Sclerosis, Relapsing-Remitting - drug therapy; Neurology; Multiple sclerosis; interleukin-17; binding antibodies to interferon; nonresponder to interferon-β; interferon-β treatment; Human; Nervous system diseases; Interleukin; Cytokine; Inflammatory disease; Treatment; Central nervous system disease; Interferon; Degenerative disease

Background: Interleukin-17 (IL-17), which is secreted by Th17 cells, is a proinflammatory cytokine that is implicated in the pathogenesis of multiple sclerosis (MS) and plays a role in nonresponse of MS patients to interferon-β (IFN-β) therapy. Objectives: The purpose of this study was to establish...